Le Lézard
Classified in: Ebola virus, Health, Science and technology, Business
Subjects: ERN, ACC

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2023


Zinzino group revenue increased with a total of 24%, compared with the previous year.

GOTHENBURG, Sweden, March 3, 2023 /PRNewswire/ -- The revenue in February for Zinzino's sales markets increased by 23 % and amounted to SEK 109.6 (89.0) million. Faun Pharma's external sales increased by 34 % and amounted to SEK 8.7 (6.5) million. Overall, the Group increased revenues by 24 % to SEK 118.3 (95.5) million compared with the previous year.

Accumulated revenue for January - February 2023 increased by 21% to SEK 247.7 (204.5) million.

Revenues were distributed as follows:

Regions,MSEK

23-Feb

22-Feb

Change

YTD 2023

YTD 2022

Change

The Nordics

23.2

21.5

8 %

46.7

47.5

-2 %

Central Europe

26.9

18.5

45 %

55.4

36.9

50 %

East Europe

25.2

23.3

8 %

58.0

52.0

12 %

South & West Europe

14.4

11.2

29 %

30.3

23.3

30 %

The Baltics

6.0

5.2

15 %

13.4

11.6

16 %

North America

6.5

4.3

51 %

12.8

8.7

47 %

Asia-Pacific

6.4

4.6

39 %

10.9

10.3

6 %

Africa

1.0

0.4

150 %

2.4

0.8

200 %

Zinzino

109.6

89.0

23 %

229.9

191.1

20 %

Faun Pharma

8.7

6.5

34 %

17.8

13.4

33 %

Zinzino Group

118.3

95.5

24 %

247.7

204.5

21 %

 

Countries in regions:

For more information:

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:

[email protected]

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: [email protected]

The following files are available for download:

https://mb.cision.com/Main/10976/3727085/1889469.pdf

2302 Pressrelease Salesreport EN


These press releases may also interest you

at 03:30
Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the publication of a...

at 03:30
Commit Biologics launches with ?16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease
Commit Biologics ("Commit"), a pioneer in the...

at 03:29
Hugel Achieves Record High Revenue for the First Quarter
Hugel, a global total medical aesthetics company, announced its 1Q24 consolidated financial results on the 9th, reporting revenue of KRW 74.3 billion, operating profit of KRW 24 billion, and net income of KRW...

at 03:00
A major advance on stroke at Montpellier University Hospital published in the New England Journal of Medicine
"LASTE" (LArge Stroke Therapy Evaluation), a prospective, randomized, controlled trial co-led by Professor Vincent Costalat (neuroradiologist, Montpellier, France) and Dr. Caroline Arquizan (vascular neurologist,...

at 03:00
Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing Company ("Tabuk"), for exclusive rights to the commercialization of...

at 03:00
Stratosphere Networks Sponsors Anixter Center's Pure Imagination Event
Stratosphere Networks has announced it will sponsor the Anixter Center's annual fundraiser. The Pure Imagination event will take place on Thursday, May 23, from 6 to 9 p.m. at Venue West at 221 N. Paulina St. in Chicago. The Anixter Center provides...

More news about Health...


News published on and distributed by: